Free Trial

CytomX Therapeutics (CTMX) Competitors

CytomX Therapeutics logo
$3.74 +0.54 (+16.88%)
Closing price 10/20/2025 04:00 PM Eastern
Extended Trading
$3.77 +0.03 (+0.80%)
As of 10/20/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CTMX vs. ETNB, SRPT, OCUL, DYN, ANIP, VERA, TLRY, TWST, COGT, and GPCR

Should you be buying CytomX Therapeutics stock or one of its competitors? The main competitors of CytomX Therapeutics include 89BIO (ETNB), Sarepta Therapeutics (SRPT), Ocular Therapeutix (OCUL), Dyne Therapeutics (DYN), ANI Pharmaceuticals (ANIP), Vera Therapeutics (VERA), Tilray Brands (TLRY), Twist Bioscience (TWST), Cogent Biosciences (COGT), and Structure Therapeutics (GPCR). These companies are all part of the "pharmaceutical products" industry.

CytomX Therapeutics vs. Its Competitors

89BIO (NASDAQ:ETNB) and CytomX Therapeutics (NASDAQ:CTMX) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, risk, media sentiment, profitability and earnings.

89BIO presently has a consensus target price of $25.81, suggesting a potential upside of 74.41%. CytomX Therapeutics has a consensus target price of $5.42, suggesting a potential upside of 44.83%. Given 89BIO's higher possible upside, research analysts plainly believe 89BIO is more favorable than CytomX Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
89BIO
1 Sell rating(s)
5 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.40
CytomX Therapeutics
0 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
3.00

In the previous week, CytomX Therapeutics had 5 more articles in the media than 89BIO. MarketBeat recorded 6 mentions for CytomX Therapeutics and 1 mentions for 89BIO. 89BIO's average media sentiment score of 0.50 beat CytomX Therapeutics' score of 0.27 indicating that 89BIO is being referred to more favorably in the media.

Company Overall Sentiment
89BIO Positive
CytomX Therapeutics Neutral

CytomX Therapeutics has higher revenue and earnings than 89BIO. 89BIO is trading at a lower price-to-earnings ratio than CytomX Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
89BION/AN/A-$367.08M-$3.61-4.10
CytomX Therapeutics$138.10M4.47$31.87M$0.566.68

CytomX Therapeutics has a net margin of 34.04% compared to 89BIO's net margin of 0.00%. CytomX Therapeutics' return on equity of 158.70% beat 89BIO's return on equity.

Company Net Margins Return on Equity Return on Assets
89BION/A -94.48% -80.92%
CytomX Therapeutics 34.04%158.70%36.04%

67.8% of CytomX Therapeutics shares are owned by institutional investors. 2.8% of 89BIO shares are owned by company insiders. Comparatively, 6.6% of CytomX Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

89BIO has a beta of 1.27, indicating that its share price is 27% more volatile than the S&P 500. Comparatively, CytomX Therapeutics has a beta of 2.27, indicating that its share price is 127% more volatile than the S&P 500.

Summary

CytomX Therapeutics beats 89BIO on 13 of the 15 factors compared between the two stocks.

Get CytomX Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CTMX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CTMX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CTMX vs. The Competition

MetricCytomX TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$527.72M$3.46B$6.14B$10.55B
Dividend YieldN/A2.27%5.72%4.84%
P/E Ratio6.6823.3929.4727.34
Price / Sales4.47488.49580.96227.67
Price / Cash8.8445.2825.8230.35
Price / Book-374.0010.6112.526.69
Net Income$31.87M-$52.56M$3.32B$276.46M
7 Day Performance9.36%3.95%1.81%-0.08%
1 Month Performance88.89%16.10%8.81%3.93%
1 Year Performance222.41%15.08%64.29%33.89%

CytomX Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CTMX
CytomX Therapeutics
4.3721 of 5 stars
$3.74
+16.9%
$5.42
+44.8%
+216.9%$527.72M$138.10M6.68170News Coverage
ETNB
89BIO
2.9408 of 5 stars
$14.80
flat
$25.81
+74.4%
+77.2%$2.19BN/A-4.1040Short Interest ↓
SRPT
Sarepta Therapeutics
4.5976 of 5 stars
$21.96
-0.7%
$34.42
+56.7%
-81.9%$2.16B$1.90B-25.241,372
OCUL
Ocular Therapeutix
4.3174 of 5 stars
$11.85
+0.6%
$22.63
+90.9%
+7.5%$2.05B$63.72M-9.26230Analyst Revision
DYN
Dyne Therapeutics
3.3321 of 5 stars
$14.03
-0.1%
$34.07
+142.8%
-51.5%$2.00BN/A-3.63100
ANIP
ANI Pharmaceuticals
3.8027 of 5 stars
$88.61
-1.3%
$99.14
+11.9%
+57.7%$1.95B$614.38M-115.08600
VERA
Vera Therapeutics
2.6998 of 5 stars
$30.49
+1.3%
$63.00
+106.6%
-26.6%$1.92BN/A-8.5240
TLRY
Tilray Brands
3.3248 of 5 stars
$1.69
-1.7%
$2.00
+18.3%
-1.3%$1.89B$821.31M-0.742,842
TWST
Twist Bioscience
3.8575 of 5 stars
$30.14
-3.4%
$48.50
+60.9%
-30.2%$1.88B$312.97M-20.79990
COGT
Cogent Biosciences
1.9989 of 5 stars
$16.20
-0.4%
$20.00
+23.5%
+36.3%$1.85BN/A-9.1080News Coverage
Gap Up
GPCR
Structure Therapeutics
3.292 of 5 stars
$30.19
+0.4%
$68.67
+127.4%
-29.4%$1.73BN/A-28.75136

Related Companies and Tools


This page (NASDAQ:CTMX) was last updated on 10/21/2025 by MarketBeat.com Staff
From Our Partners